The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia
ConclusionThis study showed for the first time the suitability of PCSK9ab treatment for reduction of platelet reactivity in FH patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 2, 2023 Category: Cardiology Source Type: research
Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information
ConclusionNumerous interactions are expected between enzalutamide or apalutamide and antithrombotics, for which management should be deployed on a case-by-case basis. PK and pharmaco-epidemiological studies could shed light on whether or not there are clinically significant events related to DDIs with antithrombotics. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 1, 2023 Category: Cardiology Source Type: research
Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies —Analysis of the WHO Pharmacovigilance Database
ConclusionRhabdomyolysis reporting was increased when ticagrelor -but not other antiplatelet agents- was notified with the most prescribed statins in practice. This finding needs to be considered by physicians especially in high-risk patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 28, 2023 Category: Cardiology Source Type: research
Impact of Low-Dose Prasugrel on Platelet Reactivity in Chronic Phase of Post-Percutaneous Coronary Intervention (CHAPERON): a Prospective Cohort Study
ConclusionsPrasugrel 2.5 mg has a lower ischemic risk and a more stable PRU value compared with clopidogrel treatment. Prasugrel also contributes to a decline in bleeding risk with concomitant dose reduction.Trial RegistrationUniversity Hospital Medical Information Network (UMIN), ID: UMIN000029541, Date: October 16, 2017 (https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033395). (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 25, 2023 Category: Cardiology Source Type: research
Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction
ConclusionImplementation of guideline-recommended cholesterol-lowering therapy could prevent a substantial percentage of recurrent ASCVD events. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 13, 2023 Category: Cardiology Source Type: research
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Significant Mitral Stenosis —a Preliminary Meta-Analysis
ConclusionsDOACs were similar to warfarin in the efficacy and safety profiles in patients with AF and concomitant significant MS. Future evidence is expected from other large trials. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 4, 2023 Category: Cardiology Source Type: research
The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof
ConclusionWe conclude that the assumption that these drugs can be used with little consequence to the aldosterone-to-renin cannot be substantiated. While it is possible that they are indeed the best option when full antihypertensive drug cessation is infeasible, the potential effects of these drugs must still be taken into account when interpreting the aldosterone-to-renin ratio. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients
ConclusionWe propose that GAC markers offer insights into the pathobiology of COVID-19, potentially guide therapeutic approaches, and could aid in early risk stratification that is particularly beneficial in phasic diseases such as COVID-19. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial
ConclusionThe RIC-AFRICA trial will determine whether RIC can reduce rates of death and heart failure in higher-risk sub-optimally reperfused STEMI patients, thereby providing a low-cost, non-invasive therapy for improving health outcomes. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic
AbstractCOVID-19 pandemic has negatively impacted the management of patients with acute and chronic cardiovascular disease: acute coronary syndrome patients were often not timely reperfused, heart failure patients not adequately followed up and titrated, atrial arrhythmias not efficaciously treated and became chronic. New phenotypes of cardiovascular patients were more and more frequent during COVID-19 pandemic and are expected to be even more frequent in the next future in the new world shaped by the pandemic. We therefore aimed to briefly summarize the main changes in the phenotype of cardiovascular patients in the COVID...
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
cFLIPL Alleviates Myocardial Ischemia-Reperfusion Injury by Inhibiting Endoplasmic Reticulum Stress
ConclusionThe expression of cFLIPL is significantly downregulated in MIRI, and it is accompanied by excessive ERS and apoptosis. Upregulated cFLIPL suppresses ERS to reduce myocardial apoptosis, which is associated with inhibiting the activity of p38 MAPK. Therefore, cFLIPL may be a potential intervention target for MIRI. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis
ConclusionsThis study identified a signal of neurocognitive disorders associated with PCSK9 inhibitors and encourages paying attention to at-risk populations. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
Pepducin ICL1-9-Mediated β2-Adrenergic Receptor-Dependent Cardiomyocyte Contractility Occurs in a Gi Protein/ROCK/PKD-Sensitive Manner
ConclusionAltogether, our study highlights a novel signaling modality that may offer a new approach to the promotion, or preservation, of cardiac contractility during HF via the allosteric regulation of β2AR to promote Gi protein/ βarr-dependent activation of RhoA/ROCK/PKD signaling. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
